StockNews.com started coverage on shares of Evoke Pharma (NASDAQ:EVOK – Free Report) in a research note issued to investors on Monday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Price Performance
NASDAQ:EVOK opened at $0.61 on Monday. Evoke Pharma has a one year low of $0.56 and a one year high of $2.42. The company has a market cap of $5.13 million, a P/E ratio of -0.26 and a beta of 0.21. The firm’s fifty day moving average price is $0.67 and its two-hundred day moving average price is $1.00. The company has a debt-to-equity ratio of 9.29, a current ratio of 2.25 and a quick ratio of 2.09.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last released its quarterly earnings data on Thursday, March 14th. The specialty pharmaceutical company reported ($0.59) EPS for the quarter. Evoke Pharma had a negative net margin of 150.43% and a negative return on equity of 517.99%. The company had revenue of $1.68 million during the quarter.
About Evoke Pharma
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Featured Articles
- Five stocks we like better than Evoke Pharma
- Most Volatile Stocks, What Investors Need to Know
- Best Bear Market Funds: Top 3 Investment Options to Consider
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Is DraftKings A Good Bet Ahead of Q1 Earnings?
- What Do S&P 500 Stocks Tell Investors About the Market?
- Mid-Cap Stocks to Outperform the Market This Cycle
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
